Skip to main content

Miracor Successfully Treats First German Patient Using the PICSO System for Severe Heart Attack Patients Post-Primary PCI

News

Miracor Successfully Treats First German Patient Using the PICSO System for Severe Heart Attack Patients Post-Primary PCI

03/26/2013

Patient underwent normal stent placement after a severe heart attack, and PICSO was applied for 90 minutes immediately following PCI, with the intent to enhance myocardial perfusion

VIENNA--(BUSINESS WIRE)--Miracor Medical Systems GmbH announced today that the first German patient was successfully treated using its PICSO (Pressure-controlledIntermittent Coronary Sinus Occlusion) System designed to improve myocardial perfusion following primary PCI (Percutaneous Coronary Intervention, or angioplasty). (Click here for video animation of PICSO.) The procedure was successfully performed by Prof. Dr. med. Stefan Sack at Schwabing Medical Center in Munich.

“We believe that there is a big unmet clinical need to improve outcomes in STEMI patients and the Miracor technology may help these patients in their recovery.”

The Miracor PICSO Impulse System, which is CE-marked, is designed to treat acute heart attack STEMI patients following coronary angioplasty. "STEMI" is an acronym meaning ST-segment Elevation Myocardial Infarction. Heart attacks are divided into three types, according to their severity. A STEMI heart attack is the most severe type. In a STEMI heart attack, the coronary artery is completely blocked off by the blood clot, and as a result virtually all the heart muscle being supplied by the affected artery starts to die.

“We are extremely pleased by this milestone achievement for our breakthrough PICSO System. We will now expand to additional German centers of excellence with CE-marked PICSO as well as conclude our ‘Prepare RAMSES’ clinical study,” said Jon H. Hoem, Miracor CEO.

“Schwabing Medical Center is very pleased to start using this technology in severe heart attack patients,” commented Prof. Sack. “We believe that there is a big unmet clinical need to improve outcomes in STEMI patients and the Miracor technology may help these patients in their recovery.”

“We fully expect that PICSO will evolve into a standard of care that complements primary PCI procedures,” added Mr. Hoem. “The fact is that in spite of a successful coronary angioplasty, impaired myocardial reperfusion still occurs in about one in three STEMI patients, and this disappointing incidence is absolutely correlated with undesirable outcomes for patients,” said Mr. Hoem. “On the other hand, PICSO is designed to solve this life-threatening condition by dramatically amplifying the redistribution of blood into the blood-starved myocardium of severe heart attack patients post-PCI. We believe that this benefit of PICSO will be heartily received by clinicians and patients.”

Copyright 2013 BusinessWire, Inc.; all rights reserved.

Back to Top